<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00152893</url>
  </required_header>
  <id_info>
    <org_study_id>03-0703-A</org_study_id>
    <secondary_id>015 027</secondary_id>
    <nct_id>NCT00152893</nct_id>
  </id_info>
  <brief_title>To Determine if Chromium Nicotinate Supplementation Will Improve Insulin Resistance in HIV Patients With Metabolic Abnormalities</brief_title>
  <official_title>The Effects of Chromium Supplementation on Glucose and Lipid Metabolism in Patients With HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johane Allard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Foundation for AIDS Research (CANFAR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <brief_summary>
    <textblock>
      In HIV patients, fasting insulin levels decrease with chromium supplementation. This study is
      to determine if chromium nicotinate supplementation at 400ug/day for 16 weeks will improve
      insulin resistance in HIV patients with metabolic abnormalities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled, crossover study where patients
      will be supplemented for 16 weeks with either chromium nicotinate 400 ug/day or placebo and
      then crossover to the opposite treatment for another 16 weeks. Each soft gel capsule of
      chromium contains 200ug of chromium and patients will take 1 capsule twice a day or its
      placebo. Placebo contains di-calcium phosphate in a soft gel capsule and its appearance is
      similar to the chromium capsules.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin resistance calculated using fasting glucose and fasting insulin levels in blood</measure>
    <time_frame>BL &amp; 16 weeks</time_frame>
    <description>HOMA-IR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hemoglobin A1c (HbA1c)</measure>
    <time_frame>BL &amp; 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood lipid profile (triglycerides [TG], cholesterol or high-density lipoprotein [HDL])</measure>
    <time_frame>BL &amp; 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body composition by dual energy x-ray absorptiometry (DEXA) scan, bioelectric impedance analysis and skin fold measurement</measure>
    <time_frame>BL &amp; 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxidative stress</measure>
    <time_frame>BL &amp; 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma chromium</measure>
    <time_frame>BL &amp; 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Chromium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 μg (200 μg pills, twice per day) of Cr-nicotinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical looking placebo (di-calcium phosphate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chromium nicotinate</intervention_name>
    <arm_group_label>Chromium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV documented patients will be considered for the study if they have at least one
             abnormality with respect to fasting blood glucose, TG, total or HDL cholesterol.
             Normal fasting glucose is defined as &lt; 6.1 mmol/L. Hypertriglyceridemia is defined as
             concentrations above 2.0 mmol/L on the basis of reports of increased risk of cardiac
             disease. Hypercholesterolemia is defined as concentrations above 5.5 mmol/L and a low
             HDL-cholesterol concentration as less than 0.9 mmol/L.

          -  Patients will need to be on a stable drug regimen for at least 8 weeks and not taking
             any chromium supplement or chromium-containing multivitamins 4 weeks prior to and
             during the study period. Patients can stay on their hypoglycemic or lipid-lowering
             medications and the required dosage will be monitored.

        Exclusion Criteria:

          -  Patients will be excluded if there is concomitant acute infection or malignancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johane Allard, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network - Toronto General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Health Network - Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Aghdassi E, Arendt B, Salit IE, Allard JP. Estimation of body fat mass using dual-energy x-ray absorptiometry, bioelectric impedance analysis, and anthropometry in HIV-positive male subjects receiving highly active antiretroviral therapy. JPEN J Parenter Enteral Nutr. 2007 Mar-Apr;31(2):135-41.</citation>
    <PMID>17308254</PMID>
  </reference>
  <results_reference>
    <citation>Aghdassi E, Arendt BM, Salit IE, Mohammed SS, Jalali P, Bondar H, Allard JP. In patients with HIV-infection, chromium supplementation improves insulin resistance and other metabolic abnormalities: a randomized, double-blind, placebo controlled trial. Curr HIV Res. 2010 Mar;8(2):113-20.</citation>
    <PMID>20163347</PMID>
  </results_reference>
  <results_reference>
    <citation>Arendt BM, Aghdassi E, Mohammed SS, Fung LY, Jalali P, Salit IE, Allard JP. Dietary intake and physical activity in a Canadian population sample of male patients with HIV infection and metabolic abnormalities. Curr HIV Res. 2008 Jan;6(1):82-90.</citation>
    <PMID>18288980</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Johane Allard</investigator_full_name>
    <investigator_title>Gastroenterologist, Prof. of Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>blood sugar &gt; 6.1 mmol/l</keyword>
  <keyword>triglycerides &gt; 2 mmol/l</keyword>
  <keyword>total cholesterol &gt; 5.5 mmol/l or HDL &lt; 0.9 mmol/l</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chromium</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

